Evonik’s biggest overhaul deepens with 3,200 job cuts and two major divestitures

Evonik Industries AG (Xetra: EVK), the Essen-based specialty chemicals group, is preparing to enter the second phase of the largest corporate restructuring in its history as management pushes ahead with job reductions, hiring restraints and major portfolio exits despite stronger-than-expected earnings in 2026. Interim Chief Executive Officer Claus Rettig has said the next restructuring phase will run from 2027 through 2029, while Evonik continues preparations to sell its Oxeno C4 chemicals business and Syneqt infrastructure company. Together, those two businesses employ about 4,300 people, although their planned divestiture should be distinguished from layoffs because employees would normally transfer with the businesses to new owners.

The workforce reduction already confirmed separately is substantial. Evonik’s Tailor Made programme and related operating-business initiatives are eliminating about 2,800 positions between 2024 and the end of 2026, while another approximately 3,200 jobs are scheduled to disappear between 2027 and 2029. Around 2,150 of the second-phase positions are in Germany, with management planning to rely on measures including hiring restraints, early retirement and voluntary separation programmes where possible.

The scale becomes clearer against Evonik’s workforce base. The company reported 31,053 employees at the end of 2025, down from 31,930 a year earlier, and employment has continued to decline during 2026. Approximately 6,000 positions are therefore covered by confirmed restructuring actions across the 2024-2029 period, before considering the separate effect that selling Oxeno and Syneqt would have on Evonik’s consolidated employee count.

Why is Evonik restructuring again when 2026 earnings have improved?

Evonik’s stronger recent results have not changed management’s view that European chemicals face structural challenges. Second-quarter adjusted EBITDA increased sharply to approximately €630 million as stronger prices, volumes and supply disruptions outside Europe supported profitability, prompting the company to raise its full-year adjusted EBITDA guidance. Management nevertheless cautioned that part of the improvement reflected temporary market conditions rather than a fundamental reversal of weak industrial demand, high European operating costs and intensifying global competition.

That distinction explains why better profits and deeper restructuring can occur simultaneously. Evonik wants to use a stronger earnings period to reduce its permanent cost base rather than wait until another downturn forces more urgent action. Temporary pricing support can improve quarterly EBITDA, but it does not resolve long-term issues such as expensive energy, excess capacity, weak regional competitiveness or businesses management believes can perform better outside the group.

The company is therefore attempting to reshape itself around higher-value specialty chemicals where technology, customer relationships and intellectual property can support more resilient margins. Businesses viewed as more cyclical, infrastructure-heavy or less strategically differentiated are increasingly being separated, sold or subjected to tighter cost controls. The goal is a smaller but more profitable Evonik capable of generating stronger cash flow through changing economic conditions.

How many Evonik jobs are being cut through 2029?

The confirmed job programme covers two major phases. Evonik expects Tailor Made and related initiatives to eliminate approximately 2,800 positions from 2024 through 2026, while the extension announced for 2027-2029 adds another roughly 3,200 positions. Management has already reported hundreds of departures during 2026 as the first phase moves toward completion.

The second phase alone represents more than 10% of Evonik’s year-end 2025 workforce, making it a material organisational restructuring rather than a routine efficiency programme. Around two-thirds of the 3,200 positions are expected to disappear in Germany, where Evonik maintains major corporate, research and manufacturing operations. The reductions will affect administrative and operating activities rather than being concentrated in one headquarters function.

Evonik intends to use socially negotiated mechanisms where possible. Vacancies may remain unfilled, eligible employees may enter early retirement and voluntary severance programmes can lower employment without relying exclusively on compulsory dismissals. Those measures can soften the immediate employment impact, but the organisation will still emerge with substantially fewer people and potentially different responsibilities for employees who remain.

What happens to the 4,300 employees at Oxeno and Syneqt?

The approximately 4,300 employees attached to Oxeno and Syneqt should not be added directly to the 3,200 confirmed job cuts. Evonik intends to divest both businesses, which means the immediate objective is to transfer their operations and employees to new ownership rather than eliminate the entire workforce. Syneqt employs roughly 3,500 people across major German chemical sites, with Oxeno accounting for much of the remaining employment associated with the planned disposals.

Oxeno contains Evonik’s C4 chemicals activities, producing intermediates used in plastics, coatings, lubricants and other industrial applications. The business has increasingly been prepared to operate independently, with dedicated functions and structures designed to make a future ownership change easier. Evonik is pursuing discussions with potential investors as it seeks to move the operation outside its long-term core portfolio.

Syneqt contains important infrastructure activities associated with large chemical sites including Marl and Wesseling. Evonik separated those operations into a more independent structure during 2026 and is preparing a sale process that could begin in 2027. The eventual buyer, ownership structure and employment consequences will depend on the transaction negotiated, making it premature to treat those employees as confirmed job losses.

Why does Evonik want Oxeno and Syneqt outside the group?

The divestitures fit Evonik’s strategy of concentrating resources on specialty chemicals where innovation and differentiated technology can generate stronger returns. Oxeno and Syneqt remain substantial operations, but they are more asset-intensive and exposed to the economics of major European chemical complexes than many of Evonik’s higher-margin specialty businesses. Removing them would make the company smaller while potentially improving its overall earnings quality and capital intensity.

Evonik increasingly wants its future portfolio centred on areas such as specialty additives, advanced materials, healthcare-related products and customised chemical solutions. These businesses can often command higher margins because products are developed around specific customer requirements rather than competing principally on commodity pricing. Management believes concentrating capital and management attention on those areas can improve both profitability and resilience.

The portfolio shift also reduces organisational complexity. Running infrastructure businesses, large-volume chemical chains and specialised high-margin products inside the same corporate structure requires different investment cycles and operating models. Divesting selected businesses allows Evonik to simplify decision-making and direct more capital toward activities where it believes it has stronger competitive advantages.

How does Tailor Made change Evonik’s management structure?

Tailor Made began as an effort to simplify administration, flatten hierarchy and give individual operating businesses greater responsibility. Evonik has repeatedly argued that its previous structure created unnecessary layers between corporate management and the businesses serving customers. Removing those layers can lower personnel costs while also accelerating decisions around pricing, investment, product development and customer relationships.

The programme therefore goes beyond reducing headcount. Management is redesigning responsibilities so that operating businesses carry more direct accountability for financial performance while central functions become smaller. This can potentially make Evonik more responsive, but it also places greater pressure on the remaining teams to handle responsibilities previously distributed across larger organisations.

The second restructuring phase extends that logic deeper into the company. Evonik wants permanent savings rather than temporary spending freezes, which means management structures, administrative processes and support activities are being examined for duplication. Hiring restraints will also contribute because positions can disappear gradually when employees leave rather than being automatically refilled.

Why are German chemical companies under such intense restructuring pressure?

Evonik’s restructuring reflects a much wider problem across Germany’s chemical industry. Energy-intensive manufacturers face high electricity and natural-gas costs, weaker European industrial demand and stronger competition from producers in regions with lower operating expenses. Chemical companies also need significant capital to modernise plants, reduce emissions and develop new technologies even when utilisation at existing facilities remains below historical levels.

Germany’s chemical industry has historically benefited from integrated production sites, skilled labour and sophisticated infrastructure, but those advantages become harder to defend when regional demand stagnates and competitors expand capacity elsewhere. Large employers are consequently reviewing factories, corporate functions and product portfolios that were built for stronger European growth. Workforce reductions are increasingly being combined with plant closures, asset sales and greater investment in specialised products that are less exposed to commodity competition.

Evonik’s approach illustrates that transition clearly. Rather than attempt to preserve every historic activity, management is separating businesses that no longer fit its desired portfolio while reducing overhead across the remaining group. The eventual organisation is expected to employ fewer people but concentrate a larger share of capital on businesses capable of producing differentiated margins.

How could the restructuring affect Evonik’s future profitability?

The central financial argument is that lower structural costs should allow a greater share of revenue to reach EBITDA and free cash flow. If Evonik can remove thousands of positions, simplify management and divest lower-return businesses without significantly damaging revenue in its core segments, profitability could become less dependent on unusually favourable pricing conditions. That would be particularly valuable during periods when chemical demand weakens or energy prices rise.

Execution remains difficult because restructuring itself carries costs. Severance packages, early-retirement agreements, business separations and transaction expenses can reduce near-term earnings even when the measures eventually generate recurring savings. Evonik must therefore balance the speed of implementation against the need to preserve technical expertise and avoid disrupting customer relationships.

Divestitures can also improve margins while reducing absolute revenue and EBITDA, making headline comparisons more complicated. Investors will need to focus increasingly on margins, cash conversion and returns on capital rather than assuming a smaller sales base represents deteriorating performance. Management’s objective is not necessarily to maximise Evonik’s size but to improve the quality of the businesses remaining inside the group.

What should Evonik employees and investors watch next?

The first milestone is completion of the initial restructuring phase at the end of 2026 and the transition into the 3,200-position programme scheduled for 2027-2029. Investors will want to see how quickly vacancies, retirements and voluntary departures reduce costs, while employees will focus on which functions and sites ultimately absorb the largest reductions. Germany is expected to carry a substantial share of the employment impact.

The second issue is the sale process for Oxeno. A transaction would provide clearer information about valuation, ownership and the future employment framework for workers inside the business. Successful divestiture would also demonstrate that Evonik can move major operations outside the group without disrupting customers or creating prolonged uncertainty.

Syneqt will become another major test once its sale process advances. Infrastructure businesses tied to large chemical sites are strategically important because multiple manufacturers can depend on services such as energy, logistics and utilities, meaning ownership changes must preserve reliable site operations. The structure of any Syneqt transaction could therefore matter to thousands of employees and other companies operating around Evonik’s German facilities.

Evonik’s restructuring has moved well beyond a conventional corporate cost programme. Roughly 6,000 positions are covered by confirmed workforce actions through 2029, while two businesses employing about 4,300 people are being prepared for new ownership. The combination means a significant proportion of the workforce associated with Evonik at the beginning of the decade will either have left the organisation or moved outside the consolidated group by the time the transformation is complete.

For employees, the most important distinction is between confirmed job reductions and divestitures that transfer employment to another owner rather than eliminate it. For investors, the larger question is whether the smaller Evonik that emerges from the restructuring can produce stronger margins, more consistent cash flow and better returns than the broader portfolio it is replacing. Management is betting that a leaner organisation focused on specialty chemicals can compete more effectively in a global industry where European scale alone is no longer enough.